Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

New

BioSim™ anti-Secukinumab (Human) ELISA Kit

A Sandwich ELISA kit for the Qualitative measurement of antibodies to Secukinumab in serum or plasma samples

WARNING: This product can expose you to chemicals including TMB, which is known to the State of California to cause cancer, For more information go to www.P65Warnings.ca.gov.
Catalog #: E5028
$1,290.00

Product Details

Cat # +Size E5028-100
Size 96 assays
Detection Method Absorbance (450 nm)
Species Reactivity Human
Applications Sandwich ELISA kit used for in vitro Qualitative determination of antibodies to Secukinumab in human serum and plasma samples
Features & Benefits ● For in vitro Qualitative determination of antibodies to Secukinumab in human serum and plasma samples
● Cross Reactivity: Except for Secukinumab, there is no cross reaction with other therapeutic antibodies and native serum immunoglobins
● Assay Precision: Intra-Assay and Inter-Assay CV < 30%
Kit Components ● Microtiter Plate
● Positive Control
● Negative Control
● Assay Buffer
● HRP-conjugate Probe
● TMB substrate (Avoid light)
● Stop Solution
● Wash buffer (20X)
● Plate sealers
Storage Conditions 4ºC
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.

Details

Secukinumab is a human IgG1 monoclonal antibody that targets IL-17α and prevents its association with the receptor IL-17R. This results in decreased release of proinflammatory cytokines and chemokines and downregulation of inflammation. IL-17 represents a family of cytokines (IL-17 A-F) released by T-helper-17 (Th17) cells, mast cells, neutrophils, and dendritic cells and promotes inflammation. Studies show that IL-17 is associated with multiple autoimmune diseases such as rheumatoid arthritis, spondyloarthritis, psoriasis, Crohn's disease, and multiple sclerosis. The original monoclonal antibody received approval from the FDA to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, upon administration of the antibody, patients tend to develop an immune response that results in the formation of anti-Secukinumab antibodies, thus adversely affecting the therapeutic response to treatment. BioSim™ anti-Secukinumab ELISA kit qualitatively measures antibodies to Secukinumab in human serum or plasma samples. The kit is based on the Sandwich ELISA principle. Standards and samples (serum or plasma) are added to the microtiter plate coated with Secukinumab. After incubation, the wells are washed. The HRP conjugated probe is added and binds to the antibodies to Secukinumab that is captured by Secukinumab coated on the wells. Following incubation, wells are washed and the enzymatic activity is detected by the addition of TMB chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of antibodies to Secukinumab in the sample or standard. The qualitative test results can be evaluated using cut-off values.


Why buy BioVision Products?
Innovation
Affordability
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.